Edition:
India

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

11.03USD
17 Aug 2018
Change (% chg)

$0.08 (+0.73%)
Prev Close
$10.95
Open
$11.00
Day's High
$11.13
Day's Low
$10.60
Volume
81,258
Avg. Vol
91,765
52-wk High
$15.08
52-wk Low
$5.45

Latest Key Developments (Source: Significant Developments)

Chemocentryx Q4 Revenue $56.3 Million Versus $4.9 Million
Friday, 9 Mar 2018 

March 9 (Reuters) - Chemocentryx Inc ::CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 REVENUE $56.3 MILLION VERSUS $4.9 MILLION.Q4 REVENUE VIEW $9.4 MILLION -- THOMSON REUTERS I/B/E/S.QUARTERLY EARNINGS PER SHARE $0.80.  Full Article

Chemocentryx reports Q3 revenue $9.0 million
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Chemocentryx Inc ::Chemocentryx reports third quarter 2017 financial results and recent highlights.Q3 revenue $9.0 million versus I/B/E/S view $9 million.Chemocentryx Inc - ‍expects to utilize cash and cash equivalents in range of $50 million and $55 million in 2017​.Chemocentryx inc - ‍phase iii advocate trial of avacopan remains on track to complete enrollment in mid-2018​.Chemocentryx Inc - ‍plan to launch registration-supporting trial for CCX140 in treatment of focal segmental glomerulosclerosis (FSGS) in Q4 2017​.Chemocentryx Inc - qtrly loss per share $0.13​.  Full Article

ChemoCentryx reports initial results from ongoing phase IB clinical trial of CCX872
Friday, 2 Sep 2016 

ChemoCentryx Inc : Reports initial results from ongoing phase IB clinical trial of CCX872 in patients with advanced pancreatic cancer . Expects to report progression-free survival (PFS) by end of 2016 . CCX872 was well tolerated by advanced pancreatic cancer patients. .Incidence and rate of adverse events were consistent with data reported historically for Folfirinox alone.  Full Article

BRIEF-Chemocentryx Q1 Revenue $9.5 Million Versus $8.2 Million

* CHEMOCENTRYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS